PLX - Protalix BioTherapeutics, Inc. Stock Price and Quote

PLX [AMEX]

Index	-	P/E	-	EPS (ttm)	-0.54	Insider Own	17.59%	Shs Outstand	50.67M	Perf Week	-5.99%
Market Cap	79.54M	Forward P/E	-	EPS next Y	-	Insider Trans	1.25%	Shs Float	41.64M	Perf Month	30.83%
Income	-	PEG	-	EPS next Q	-0.15	Inst Own	9.70%	Short Float / Ratio	4.95% / 4.35	Perf Quarter	53.92%
Sales	47.57M	P/S	1.67	EPS this Y	37.10%	Inst Trans	-	Short Interest	2.06M	Perf Half Y	46.73%
Book/sh	-0.23	P/B	-	EPS next Y	-	ROA	-	Target Price	-	Perf Year	90.97%
Cash/sh	-	P/C	-	EPS next 5Y	25.00%	ROE	-	52W Range	0.70 - 2.00	Perf YTD	14.60%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-21.50%	Beta	-
Dividend %	-	Quick Ratio	-	Sales past 5Y	-	Gross Margin	-	52W Low	124.29%	ATR	0.11
Employees	202	Current Ratio	-	Sales Q/Q	17.70%	Oper. Margin	-	RSI (14)	57.27	Volatility	12.81% 6.92%
Optionable	Yes	Debt/Eq	-	EPS Q/Q	-	Profit Margin	-	Rel Volume	1.34	Prev Close	1.52
Shortable	Yes	LT Debt/Eq	-	Earnings	Nov 14 BMO	Payout	-	Avg Volume	474.00K	Price	1.57
Recom	2.00	SMA20	4.11%	SMA50	21.73%	SMA200	36.39%	Volume	636,744	Change	3.29%

Jun-08-20

Reiterated

H.C. Wainwright

Buy

$3 → $11

Apr-17-17

Reiterated

Rodman & Renshaw

Buy

$4 → $5

Apr-04-16

Initiated

Rodman & Renshaw

Buy

$3.50

Apr-23-15

Upgrade

Jefferies

Hold → Buy

$2 → $2.60

Nov-12-14

Reiterated

R. F. Lafferty

Buy

$8 → $5

Jan-24-14

Initiated

R. F. Lafferty

Buy

May-02-12

Reiterated

Oppenheimer

Outperform

$9 → $11

May-02-12

Downgrade

Canaccord Genuity

Buy → Hold

$8 → $8

Apr-30-12

Downgrade

Auriga

Buy → Hold

$8 → $8

Oct-13-11

Initiated

Morgan Joseph

Hold

Show Previous Ratings

Jan-06-23 07:04AM	Daily Vickers Top Buyers & Sellers for 01/06/2023 Argus Research +6.99%
Jan-03-23 06:50AM	Protalix BioTherapeutics Issues 2023 Letter to Stockholders PR Newswire
Dec-21-22 04:30PM	Protalix BioTherapeutics to Delist its Common Stock from the Tel Aviv Stock Exchange PR Newswire
Dec-05-22 06:50AM	Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce U.S. Food and Drug Administration Acceptance of a Resubmitted Biologics License Application for Pegunigalsidase Alfa for the Proposed Treatment of Fabry Disease PR Newswire +5.31%
Dec-04-22 09:00AM	Protalix Biotherapeutics Hosting Key Opinion Leader Webinar on Fabry Disease and PRX-102 PR Newswire
02:59PM	Loading…
Nov-30-22 02:59PM	Protalix and Chiesi Resubmit FDA Application For Rare Disease Treatment News Direct
Nov-15-22 04:46AM	PLX: BLA Submitted: 1H:23 Responses Zacks Small Cap Research
Nov-14-22 06:50AM	Protalix BioTherapeutics Reports Third Quarter 2022 Financial and Business Results PR Newswire
06:30AM	Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Resubmission of Biologics License Application to U.S. Food and Drug Administration for Pegunigalsidase Alfa for the Treatment of Fabry Disease PR Newswire
Nov-07-22 06:50AM	Protalix BioTherapeutics to Report Third Quarter 2022 Financial and Business Results on November 14, 2022 PR Newswire
Sep-21-22 08:00AM	Under The Hood Of Options Chain Implications Understanding How Options Data Can Help Inform Investment Decisions News Direct
Sep-12-22 12:40PM	Protalix BioTherapeutics to Present in Person at the H.C. Wainwright 24th Annual Global Investment Conference PR Newswire
Sep-06-22 06:50AM	Protalix BioTherapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference PR Newswire
Aug-16-22 05:55AM	PLX: Eyes on Upcoming BLA Resubmission Zacks Small Cap Research
Aug-15-22 06:50AM	Protalix BioTherapeutics Reports Second Quarter 2022 Financial and Business Results PR Newswire
06:50AM	Loading…
Aug-08-22 06:50AM	Protalix BioTherapeutics to Announce Second Quarter 2022 Financial and Business Results Conference Call on August 15, 2022 PR Newswire
Jun-30-22 04:30PM	Protalix BioTherapeutics Appoints Shmuel "Muli" Ben Zvi, Ph.D. to its Board of Directors PR Newswire
Jun-14-22 09:23AM	10 Popular Penny Stocks on Robinhood Insider Monkey
May-26-22 04:30PM	Protalix BioTherapeutics Announces Poster Presentations at the 2022 Program: 7th Update on Fabry Disease PR Newswire
May-17-22 06:13AM	PLX: First Quarter Financial and Operational Review Zacks Small Cap Research
May-16-22 06:50AM	Protalix BioTherapeutics Reports First Quarter 2022 Financial and Business Results PR Newswire
May-09-22 06:50AM	Protalix BioTherapeutics to Announce First Quarter 2022 Financial and Business Results Conference Call on May 16, 2022 PR Newswire -7.49%
Apr-07-22 10:05AM	10 Penny Stocks to Buy in April Insider Monkey -9.62%
Apr-05-22 07:40AM	PLX: Topline Results from BALANCE Zacks Small Cap Research
Apr-04-22 06:50AM	Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Topline Results from the 24-Month Phase III BALANCE Clinical Trial of PRX-102 for the Treatment of Fabry Disease PR Newswire +41.90%
Apr-01-22 06:22AM	PLX: Fourth Quarter and Fiscal Year 2021 Financial and Operational Review Zacks Small Cap Research
Mar-31-22 06:50AM	Protalix BioTherapeutics Reports Fiscal Year 2021 Financial and Business Results PR Newswire
Mar-24-22 06:50AM	Protalix BioTherapeutics to Hold Fiscal Year 2021 Financial and Business Results Conference Call on March 31, 2022 PR Newswire
Mar-18-22 09:54AM	Protalix Bio, Chiesi Release Final Results From Late-Stage PRX-102 Trial In Fabry Disease Benzinga +12.89%
06:50AM	Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Final Results of the BRIGHT Phase III Clinical Trial Evaluating PRX-102 for the Treatment of Fabry Disease PR Newswire
07:00AM	Loading…
Mar-07-22 07:00AM	Revenue Diversification Strategy Continues to Deliver CNW Group
Feb-28-22 04:45AM	PLX: MAA Submitted Zacks Small Cap Research
Feb-24-22 07:27AM	Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce the Submission of a Marketing Authorization Application to the European Medicines Agency for PRX-102 for the Treatment of Fabry Disease PR Newswire
Feb-03-22 06:50AM	Protalix BioTherapeutics to Participate in the 18th Annual WORLDSymposium 2022 PR Newswire
Dec-22-21 06:50AM	Protalix BioTherapeutics Issues 2021 Letter to Stockholders PR Newswire
Nov-15-21 10:18AM	PLX: Third Quarter Update Zacks Small Cap Research
06:50AM	Protalix BioTherapeutics Reports Third Quarter 2021 Financial Results and Provides Financial and Business Update PR Newswire
Nov-08-21 06:50AM	Protalix BioTherapeutics to Release Third Quarter 2021 Financial Results and Provide a Financial and Business Update on November 15, 2021 PR Newswire
Oct-15-21 08:37AM	Protalix Biotherapeutics and Chiesi Global Rare Diseases Announce Final Dosing of Last Patient in Phase III BALANCE Clinical Trial PRX-102 for the Treatment of Fabry Disease PR Newswire
08:00AM	PLX: Type A Meeting Provides Clarity Zacks Small Cap Research
Oct-11-21 06:50AM	Protalix Biotherapeutics and Chiesi Global Rare Diseases Provide Regulatory Update on PRX-102 for the Treatment of Fabry Disease PR Newswire -12.78%
Aug-26-21 06:50AM	Protalix BioTherapeutics Announces Closing of Private Note Exchange PR Newswire
Aug-18-21 06:06AM	PLX: Debt Maturities Resolved Zacks Small Cap Research
Aug-16-21 06:50AM	Protalix BioTherapeutics Reports Second Quarter 2021 Financial Results and Financial and Business Update PR Newswire
Aug-13-21 06:50AM	Protalix BioTherapeutics Announces Private Note Exchange PR Newswire -9.46%
Aug-09-21 07:15AM	Protalix BioTherapeutics to Release Second Quarter 2021 Financial Results and Provide a Financial and Business Update on August 16, 2021 PR Newswire +7.33%
Aug-02-21 06:50AM	Protalix BioTherapeutics Announces Submission of Type A Meeting Request to the FDA PR Newswire
Jun-30-21 09:56AM	Is Protalix BioTherapeutics Inc. (PLX) A Good Stock To Buy? Insider Monkey
Jun-28-21 06:50AM	Protalix BioTherapeutics to Participate in a Fireside Chat on June 30, 2021 PR Newswire
Jun-07-21 10:18PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Protalix BioTherapeutics, Inc. - PLX GlobeNewswire
Jun-05-21 08:16PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Protalix BioTherapeutics, Inc. - PLX Newsfile
Jun-03-21 09:28AM	PLX: BALANCE: Interim Results Zacks Small Cap Research -10.48%
09:28AM	PLX: BALANCE: Interim Analysis Zacks Small Cap Research
12:30AM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Protalix BioTherapeutics, Inc. - PLX PR Newswire
Jun-02-21 12:10PM	Protalix Shares Hits 52-Week Low After Adverse Event Reported In Fabry Disease Trial With PRX-102 Benzinga -16.78%
06:50AM	Protalix Biotherapeutics and Chiesi Global Rare Diseases Provide Update Regarding Clinical Development of PRX-102 for Treatment of Fabry Disease PR Newswire
May-25-21 06:50AM	PLX: 1Q:21 Results & Next Steps Zacks Small Cap Research
May-14-21 06:50AM	Protalix BioTherapeutics Reports First Quarter 2021 Financial Results and Business Update PR Newswire
06:45AM	Protalix Biotherapeutics, Inc. to Host Earnings Call ACCESSWIRE
May-07-21 10:30AM	Protalix BioTherapeutics to Hold First Quarter 2021 Financial and Business Results Conference Call on May 14, 2021 PR Newswire
Apr-29-21 05:45AM	PLX: Pandemic Backup Impedes FDA Site Survey Zacks Small Cap Research -9.92%
Apr-28-21 03:25PM	Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Protalix BioTherapeutics, Inc. (PLX) Investigation ACCESSWIRE -32.59%
01:44PM	Why Protalix BioTherapeutics Stock Is Plunging Today Motley Fool
01:27PM	Protalix BioTherapeutics Provides Update on Complete Response Letter for Pegunigalsidase Alfa from the FDA PR Newswire
06:21AM	Protalix Stock Falls After FDA Slaps CRL For PRX-102 Application In Fabry Disease Benzinga
01:50AM	Protalix BioTherapeutics and Chiesi Global Rare Diseases Receive Complete Response Letter for Pegunigalsidase Alfa from FDA PR Newswire
Apr-07-21 05:15AM	PLX: Target Action Date Four Weeks Away Zacks Small Cap Research
Mar-30-21 06:50AM	Protalix BioTherapeutics Reports Fiscal Year 2020 Financial and Business Results PR Newswire
06:30AM	Protalix Biotherapeutics, Inc. to Host Earnings Call ACCESSWIRE
Mar-22-21 06:50AM	Protalix BioTherapeutics to Hold Fiscal Year 2020 Financial and Business Results Conference Call on March 30, 2021 PR Newswire +6.67%
Mar-04-21 06:50AM	Protalix BioTherapeutics to Present at the H.C. Wainwright Global Life Sciences Conference PR Newswire -11.21%
Feb-24-21 08:03AM	PLX: A Busy Month Zacks Small Cap Research +11.33%
Feb-23-21 08:04AM	Protalix's PRX102 Monthly Treatment Shows Benefit In Fabry Disease Benzinga
07:25AM	The Daily Biotech Pulse: Aridis To Study Antibody Cocktail For Coronavirus Variants, Revance & Protalix Data Readouts Benzinga
06:50AM	Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Positive Topline Results from BRIGHT Phase III Open-Label, Switch-Over Clinical Trial Evaluating Pegunigalsidase Alfa 2 mg/kg every Four Weeks for Treatment of Fabry Disease PR Newswire
Feb-22-21 03:20AM	Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) Is About To Turn The Corner Simply Wall St.
Feb-18-21 08:02AM	Protalix BioTherapeutics Completes Raise of Approximately $40 Million in Gross Proceeds PR Newswire
Feb-12-21 05:54AM	Protalix BioTherapeutics Raises $35M Via Equity At 21% Discount Benzinga -15.37%
Feb-11-21 09:16PM	Protalix BioTherapeutics Announces Pricing of its Upsized Public Offering of Common Stock PR Newswire
04:35PM	Protalix BioTherapeutics Announces Proposed Public Offering of Common Stock PR Newswire
07:47AM	Protalix BioTherapeutics Perks Up On Alidornase Alfa Licensing Pact In Respiratory Conditions Benzinga
07:26AM	The Daily Biotech Pulse: DermTech Soars On Contract, Fluidigm Plunges On Earnings, Decision Day For Regeneron, Bioventus Debuts Benzinga
06:50AM	Protalix BioTherapeutics Enters into an Exclusive Partnership with SarcoMed USA to Develop alidornase alfa for the Treatment of Pulmonary Sarcoidosis and Related Respiratory Diseases Via Inhaled Delivery PR Newswire
Feb-10-21 07:01AM	Protalix BioTherapeutics and Chiesi Global Rare Diseases Present Key Clinical Data of Pegunigalsidase Alfa for the Treatment of Fabry Disease at the 17th Annual WORLDSymposium 2021 PR Newswire -10.85%
Feb-01-21 06:50AM	Protalix BioTherapeutics Announces Presentations at the 17th Annual WORLDSymposium 2021 PR Newswire
Jan-04-21 06:50AM	Protalix BioTherapeutics to Participate in Upcoming Investor Conferences in January PR Newswire
04:25AM	PLX: Final Results for BRIDGE and A Letter to Shareholders Zacks Small Cap Research
Dec-30-20 06:50AM	Protalix BioTherapeutics Issues 2020 Letter to Shareholders PR Newswire
06:00AM	Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Final Results of BRIDGE Phase III Open-Label, Switch-Over Clinical Trial Evaluating Pegunigalsidase Alfa for the Treatment of Fabry Disease PR Newswire
Dec-21-20 06:40AM	Have Insiders Been Buying Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) Shares This Year? Simply Wall St.
Dec-15-20 07:15AM	PLX: FDA Approval To Start New Chapter Zacks Small Cap Research +5.90%
Nov-30-20 03:38PM	Is Protalix BioTherapeutics Inc. (PLX) A Good Stock To Buy Now? Insider Monkey
Nov-27-20 06:50AM	Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Extension of PDUFA Date for Pegunigalsidase Alfa for the Proposed Treatment of Fabry Disease PR Newswire -5.97%
Nov-05-20 06:50AM	Protalix BioTherapeutics to Present at the H.C. Wainwright 6th Annual Israel Conference PR Newswire
Oct-29-20 01:33PM	Protalix BioTherapeutics to Reschedule Third Quarter 2020 Financial Results and Business Update Call for Friday, October 30 PR Newswire -5.63%
06:50AM	Protalix BioTherapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update PR Newswire
06:30AM	Protalix Biotherapeutics, Inc. to Host Earnings Call ACCESSWIRE
Oct-26-20 06:50AM	Protalix BioTherapeutics to Participate in Virtual Investor KOL Roundtable PR Newswire
Oct-22-20 06:50AM	Protalix BioTherapeutics to Hold Third Quarter 2020 Financial Results and Business Update Conference Call on October 29, 2020 PR Newswire
Oct-20-20 12:13PM	Do Institutions Own Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) Shares? Simply Wall St.

Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in the last stage of clinical trials for the treatment of Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundacao Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was founded in 1993 and is based in Hackensack, New Jersey.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Schwartz Aharon	Director	Jan 03	Buy	1.42	110,000	155,815	174,000	Jan 05 05:08 PM
Bashan Dror	President and CEO	Apr 11	Buy	1.50	68,000	102,000	68,000	Apr 13 04:05 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Upgrade your FINVIZ experience